Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is gaining momentum and
demonstrating durable responses in patients with advanced melanoma. Although …

Chemoimmunotherapy is currently the preferred first-line treatment option for the majority of
patients with advanced non–small cell lung cancer without driver genetic alterations. Most of …

Engineering tumor infiltrating lymphocytes from sarcoma and colorectal tumors with membrane
bound IL-15 for IL-2 independent exp Page 1 Engineering tumor infiltrating lymphocytes from …